glp-1 colorectal cancer risk study november 2025 Could medications help slow progression?⁣ ⁣ A new Cleveland Clinic found those taking GLP-1s were less likely to develop stage IV disease in several cancer types, when compared to GLP-1 receptor agonist initiation and

Why Choose BFF Medical Wellness Clinic

Are GLP-1-type medications safe

This is consistent, the team said, with the prevailing hypothesis suggesting that [semaglutides] therapeutic effects arise from overlapping neurobiological mechanisms that modulate both metabolic regulation and reward-related pathways shared between obesity and alcohol use disorder. The team concluded: Findings from this trial provide support for broadening the indication for semaglutide to [include] AUD in patients with a BMI of 30 or greater, which could benefit millions. About 890 million adults globally have a BMI over 30, and in the U.S., 8 million adults are estimated to have obesity and high alcohol consumption

Our previous guides addressed new indications and their impact on employers and payers, as well as early outcomes of Omadas Enhanced GLP-1 Care Track

38 As of December 31, 2025 CASH RUNWAY EXPECTED INTO 2028 $317M in cash, cash equivalents, and short-term investments THROUGH THE POTENTIAL APPROVAL ~110M shares outstanding AND LAUNCH OF AVEXITIDE IN 2027 39 Team Leadership Team Tenured in Rare Disease with Commercial and Clinical Development Capabilities Joshua Cohen, BSE Justin Klee, ScB Jim Frates Camille L